This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The Starplex acquisition supports Pretium’s growth objectives in the medical and consumer healthcare market sectors.
Starplex Scientific has built highly-respected product lines including leak-resistant sterilized containers, biological sampling swabs and pharmaceutical grade containers and closures. Its products serve the clinical, laboratory and drug manufacturing markets in the United States and Canada.
Products are produced from ISO13485-certified operations in Toronto and Cleveland, Tennessee, with a combined 200,000–plus square feet of manufacturing space.
In keeping with Pretium’s ongoing acquisition philosophy, existing employees and the Starplex Scientific brand will be retained.
“The acquisition of Starplex Scientific is another example of Pretium merging independent, well-run companies with strong brand presence, a robust product line and complementary geographic locations into our existing family of companies. Starplex’s quality systems and medical device knowledge, will be welcome additions to our growing healthcare market segment.” said Paul Kayser, president and chief executive officer of Pretium.
David Golde, managing director at Genstar Capital, stated, “Genstar is pleased to be sponsoring Pretium’s acquisition of Starplex Scientific. The acquisition represents the seventh completed during Genstar’s ownership. Starplex has a well-respected brand and market presence in medical consumables and healthcare packaging, both of which represent key areas of continued investment and growth for Pretium.”
